Merck KGaA could now have a head start in the race to market Precem-TcT, which could become the first widely approved ADC in ...

Patients with untreated advanced melanoma do not appear to gain a survival advantage from the addition of a cancer vaccine to pembrolizumab, suggests a trial.

Leticia Detrow didn’t have much of a choice. Her sprinting times had plateaued. And, unbeknownst to her, Randy Shank, her track coach at Maryland School for the Deaf, had signed her up for a pair of ...

Patients with chemorefractory metastatic colorectal cancer derive no overall survival benefit from giving anti-EGFR ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug ...

US FDA grants priority review for Keytruda & Keytruda Qlex, each in combination with Padcev, for certain patients with muscle-invasive bladder cancer: Rahway, New Jersey Friday, O ...

RoundTable Healthcare Partners ("RoundTable"), an operating-oriented private equity firm focused exclusively on the healthcare industry, announced today that it has completed the sale of its minority ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response ...

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

Several weekend activities that were scheduled in the St. Louis area for Saturday have been either postponed or canceled due ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company’s cardio-pulmonary portfolio and pipeline at the American Heart ...